This study investigated the expression and localization of cathepsins B, D, and G in relationship to the embryonic stem cell (ESC)-like population we have previously identified in microcystic lymphatic malformation (mLM).
Methods and Results:
Immunohistochemical staining demonstrated expression of cathepsins B, D, and G in cervicofacial mLM tissue samples from 11 patients. Immunofluorescence staining of two representative mLM samples showed localization of cathepsins B and D to the OCT4+ and the c-MYC+ cells on the endothelium of lesional vessels and the stroma, while cathepsin G was localized to the OCT4+/tryptase+ cells within the stroma. Transcript expression of cathepsins B, D, and G was confirmed using reverse transcription quantitative polymerase chain reaction (RT-qPCR; n = 5). Western blotting (n = 3) performed on the mLM tissue samples revealed protein expression of cathepsins B and D, which were demonstrated to be enzymatically active using enzymatic activity assays.
Conclusion:
This study demonstrated expression of cathepsins B and D by the ESC-like cells on the endothelium of lesional vessels and the stroma, while cathepsin G was localized to the OCT4+ phenotypic mast cells within the stroma of mLM.
Get full access to this article
View all access options for this article.
References
1.
Garcia-MonteroP, Del BozJ, Sanchez-MartinezM, Escudero SantosIM, BaselgaE. Microcystic lymphatic malformation successfully treated with topical rapamycin. Pediatrics, 2017; 139:e20162105.
2.
WiegandS, EivaziB, ZimmermannAP, et al.Microcystic lymphatic malformations of the tongue: Diagnosis, classification, and treatment. Arch Otolaryngol Head Neck Surg, 2009; 135:976–983.
3.
VogelAM, WarnerBW. Toward an understanding of lymphatic malformations. Gastroenterol Hepatol, 2013; 9:195–196.
4.
PerkinsJA, ManningSC, TemperoRM, et al.Lymphatic malformations: Current cellular and clinical investigations. Otolaryngol Head Neck Surg, 2010; 142:789–794.
RavehE, de JongAL, TaylorGP, ForteV. Prognostic factors in the treatment of lymphatic malformations. Arch Otolaryngol Head Neck Surg, 1997; 123:1061–1065.
12.
EadyEK, BraschHD, de JonghJ, MarshRW, TanST, ItinteangT. Expression of embryonic stem cell markers in microcystic lymphatic malformation. Lymphat Res Biol, 2019; 17:496–503.
13.
MunroMJ, WickremesekeraAC, DavisPF, MarshR, TanST, ItinteangT. Renin-angiotensin system and cancer: A review. Integr Cancer Sci Therap, 2017; 4:1–6.
14.
TanEMS, BraschHD, DavisPF, ItinteangT, TanST. Embryonic stem cell-like population within venous malformation expresses the renin-angiotensin system. Plast Reconstr Surg Glob Open, 2019; 7:e2170.
15.
SiljeeS, KeaneE, MarshR, BraschHD, TanST, ItinteangT. Expression of the components of the renin-angiotensin system in venous malformation. Front Surg, 2016; 3:24.
16.
ItinteangT, BraschHD, TanST, DayDJ. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg, 2011; 64:759–765.
17.
Papali'i-CurtinJC, BraschHD, van SchaijikB, et al.Expression of components of the renin-angiotensin system in pyogenic granuloma. Front Surg, 2019; 6:13.
18.
GeorgeAJ, ThomasWG, HannanRD. The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer, 2010; 10:745–759.
19.
ItinteangT, ChudakovaDA, DunneJC, DavisPF, TanST. Expression of cathepsins B, D, and G in infantile hemangioma. Front Surg, 2015; 2:26.
20.
KohSP, WickremesekeraAC, BraschHD, MarshR, TanST, ItinteangT. Expression of cathepsins B, D, and G in isocitrate dehydrogenase-wildtype glioblastoma. Front Surg, 2017; 4:28.
21.
YetkinE, OzturkS. Dilating vascular diseases: Pathophysiology and clinical aspects. Int J Vasc Med, 2018; 2018:9024278.
22.
AokiT, KataokaH, IshibashiR, NozakiK, HashimotoN. Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. Stroke, 2008; 39:2603–2610.
23.
XuN, ZhangYY, LinY, et al.Increased levels of lysosomal cysteinyl cathepsins in human varicose veins: A histology study. Thromb Haemost, 2014; 111:333–344.
24.
PatersonC, LeeVMY, BraschHD, et al.Expression of cathepsins B, D, and G by the embryonic stem cell-like population within human keloid tissues and keloid-derived primary cell lines. Plast Reconstr Surg, 2019; 144:1338–1349.
25.
TanK, BraschHD, van SchaijikB, et al.Expression and localization of cathepsins B, D, and G in Dupuytren's disease. Plast Reconstr Surg Glob Open, 2018; 6:e1686.
26.
MillerDD, GuptaA. Histopathology of vascular anomalies: Update based on the revised 2014 ISSVA classification. Sem Cutan Med Surg, 2016; 35:137–146.
27.
MehrotraS, WickremesekeraSK, BraschHD, et al.Expression and localization of cathepsins B, D and G in cancer stem cells in liver metastasis from colon adenocarcinoma. Front Surg, 2018; 5:40.
28.
QinY, ShiGP. Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases. Pharmacol Ther, 2011; 131:338–350.
SukhovaGK, ShiGP. Do cathepsins play a role in abdominal aortic aneurysm pathogenesis?. Ann N Y Acad Sci, 2006; 1085:161–169.
31.
RibattiD, NicoB, FinatoN, CrivellatoE, BeltramiCA. Co-localization of tryptase and cathepsin-G in mast cells in cutaneous mastocytosis. Cancer Lett, 2009; 279:209–212.
32.
ZhouZ, WangY, BryantSH. Computational analysis of the cathepsin B inhibitors activities through LR-MMPBSA binding affinity calculation based on docked complex. J Comput Chem, 2009; 30:2165–2175.
33.
LiYY, FangJ, AoGZ. Cathepsin B and L inhibitors: A patent review (2010–present). Expert Opin Ther Pat, 2017; 27:643–656.
34.
RavishI, RaghavN. Curcumin as inhibitor of mammalian cathepsin B, cathepsin H, acid phosphatase and alkaline phosphatase: A correlation with pharmacological activities. Med Chem Res, 2014; 23:2847–2855.
35.
DumasJ, BrittelliD, ChenJ, et al.Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett, 1999; 9:2531–2536.
36.
HuoS, WangJ, CieplakP, KollmanPA, KuntzID. Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: Insight into structure-based ligand design. J Med Chem, 2002; 45:1412–1419.
37.
GrecoMN, HawkinsMJ, PowellET, et al.Nonpeptide inhibitors of cathepsin G: Optimization of a novel beta-ketophosphonic acid lead by structure-based drug design. J Am Chem Soc, 2002; 124:3810–3811.
38.
SwedbergJE, LiCY, de VeerSJ, WangCK, CraikDJ. Design of potent and selective cathepsin G inhibitors based on the sunflower trypsin inhibitor-1 scaffold. J Med Chem, 2017; 60:658–667.
39.
HumphriesH, BraschHD, van SchaijikB, TanST, ItinteangT. Expression of components of the renin-angiotensin system by the embryonic stem cell-like population within keloid lesions. Plast Reconstr Surg, 2019; 144:372–384.
40.
OnN, KohSP, BraschHD, et al.Embryonic stem cell-like population in Dupuytren's disease expresses components of the renin-angiotensin system. Plast Reconstr Surg Glob Open, 2017; 5:e1422.
41.
ItinteangT, MarshR, DavisPF, TanST. Angiotensin II causes cellular proliferation in infantile haemangioma via angiotensin II receptor 2 activation. J Clin Pathol, 2015; 68:346–350.
42.
ZambidisET, ParkTS, YuW, et al.Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood, 2008; 112:3601–3614.
43.
PinterM, JainRK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med, 2017; 9:eaan5616.
44.
FeatherstonT, MarshRW, van SchaijikB, BraschHD, TanST, ItinteangT. Expression and localization of cathepsins B, D, and G in two cancer stem cell subpopulations in moderately differentiated oral tongue squamous cell carcinoma. Front Med (Lausanne), 2017; 4:100.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
